Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Sullivan

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
The American Journal of Tropical Medicine and Hygiene|November 6, 2007
Relationship of hepcidin with parasitemia and anemia among patients with uncomplicated Plasmodium falciparum malaria in GhanaCaitlin T Howard, Uri S McKakpo, Isabella A Quakyi, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
AIDS (London, England)|November 6, 2003
The effects of placental malaria on mother-to-child HIV transmission in Rakai, UgandaHeena Brahmbhatt, Godfrey Kigozi, Fred Wabwire-Mangen, et al.
Cardiovascular Drugs and Therapy|August 4, 2018
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension StudiesLeslie Cho, Ricardo Dent, Erik S G Stroes, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Journal of Paediatrics and Child Health|June 9, 2009
Costs of managing conditions associated with obesity among Australian teenagersMichael L Booth, Timothy Dobbins, Robert Aitken, et al.
Diabetes Research and Clinical Practice|August 25, 2011
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD studyDavid Sullivan, Peta Forder, John Simes, et al.
Heart (British Cardiac Society)|March 3, 2017
Gender inequalities in cardiovascular risk factor assessment and management in primary healthcareKarice K Hyun, Julie Redfern, Anushka Patel, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
The American Journal of Tropical Medicine and Hygiene|November 6, 2007
Relationship of hepcidin with parasitemia and anemia among patients with uncomplicated Plasmodium falciparum malaria in GhanaCaitlin T Howard, Uri S McKakpo, Isabella A Quakyi, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
AIDS (London, England)|November 6, 2003
The effects of placental malaria on mother-to-child HIV transmission in Rakai, UgandaHeena Brahmbhatt, Godfrey Kigozi, Fred Wabwire-Mangen, et al.
Cardiovascular Drugs and Therapy|August 4, 2018
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension StudiesLeslie Cho, Ricardo Dent, Erik S G Stroes, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Journal of Paediatrics and Child Health|June 9, 2009
Costs of managing conditions associated with obesity among Australian teenagersMichael L Booth, Timothy Dobbins, Robert Aitken, et al.
Diabetes Research and Clinical Practice|August 25, 2011
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD studyDavid Sullivan, Peta Forder, John Simes, et al.
Heart (British Cardiac Society)|March 3, 2017
Gender inequalities in cardiovascular risk factor assessment and management in primary healthcareKarice K Hyun, Julie Redfern, Anushka Patel, et al.
Pageof 19